Danaher (NYSE:DHR) Stock Acquired Rep. Thomas H. Kean, Jr.

Key Points

• Representative Thomas H. Kean, Jr. purchased shares of Danaher Corporation (NYSE:DHR) between $1,001 and $15,000 on June 11th, disclosing the transaction on July 16th.
• Danaher stock recently rose by 1.1%, trading at $204.97 with significant trading volumes below its average.
• The company reported $1.80 earnings per share in its latest quarter, exceeding analyst expectations, alongside $5.94 billion in revenue.
• Danaher also announced a quarterly dividend of $0.32 per share, reflecting a 0.62% yield and a dividend payout ratio of 27.23%.

Representative Thomas H. Kean, Jr. (R-New Jersey) recently bought shares of Danaher Corporation NYSE: DHR. In a filing disclosed on July 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Danaher stock on June 11th. The trade occurred in the Representative's "KEAN FAMILY PARTNERSHIP" account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 6/30/2025.
• Sold $15,001 - $50,000 in shares of Stryker NYSE: SYK on 6/26/2025.
• Sold $1,001 - $15,000 in shares of WESCO International NYSE: WCC on 6/23/2025.
• Purchased $1,001 - $15,000 in shares of AON NYSE: AON on 5/27/2025.
• Purchased $1,001 - $15,000 in shares of Becton, Dickinson and Company NYSE: BDX on 5/13/2025.
• Sold $1,001 - $15,000 in shares of Crown NYSE: CCK on 5/8/2025.
• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 5/8/2025.
• Purchased $1,001 - $15,000 in shares of Thermo Fisher Scientific NYSE: TMO on 5/5/2025.
• Sold $1,001 - $15,000 in shares of Franklin Resources NYSE: BEN on 4/28/2025.
• Purchased $1,001 - $15,000 in shares of Analog Devices NASDAQ: ADI on 4/24/2025.

Danaher Price Performance

Shares of NYSE DHR traded up $2.79 during mid-day trading on Friday, reaching $205.60. 5,355,676 shares of the company were exchanged, compared to its average volume of 3,965,185. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $147.22 billion, a PE ratio of 43.74, a PEG ratio of 2.86 and a beta of 0.77. The company's 50 day moving average price is $196.38 and its 200 day moving average price is $203.68.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.72 EPS. Sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, July 25th. Shareholders of record on Friday, June 27th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.62%. Danaher's payout ratio is 27.23%.

Insider Activity at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares in the company, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Danaher

A number of institutional investors have recently made changes to their positions in the company. GHP Investment Advisors Inc. lifted its position in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the period. Heck Capital Advisors LLC bought a new position in Danaher during the fourth quarter valued at approximately $27,000. Sierra Ocean LLC lifted its position in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares during the period. Red Tortoise LLC lifted its position in Danaher by 175.0% during the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate's stock valued at $30,000 after purchasing an additional 98 shares during the period. Finally, Smallwood Wealth Investment Management LLC bought a new position in Danaher during the first quarter valued at approximately $31,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on DHR shares. Robert W. Baird upped their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Citigroup reaffirmed a "buy" rating on shares of Danaher in a research note on Monday, April 7th. Guggenheim reiterated a "buy" rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday. JPMorgan Chase & Co. reduced their price target on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 22nd. Finally, Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research report on Friday, July 11th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $247.61.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.